We aim to fundamentally change the global healthcare. We believe that collaboration is the key for shared success and global impact. We are actively looking for out-licensing opportunities within molecular diagnostic players. 

Our current focus within liquid biopsies is MRD & Tx selection and we continuously monitor potential new verticals for collaboration.